You just read:

Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia

News provided by

Celator Pharmaceuticals, Inc.

Jun 14, 2016, 07:00 ET